Jeffrey A. Cohen

31.8k total citations · 9 hit papers
314 papers, 22.7k citations indexed

About

Jeffrey A. Cohen is a scholar working on Pathology and Forensic Medicine, Neurology and Molecular Biology. According to data from OpenAlex, Jeffrey A. Cohen has authored 314 papers receiving a total of 22.7k indexed citations (citations by other indexed papers that have themselves been cited), including 164 papers in Pathology and Forensic Medicine, 91 papers in Neurology and 64 papers in Molecular Biology. Recurrent topics in Jeffrey A. Cohen's work include Multiple Sclerosis Research Studies (163 papers), Peripheral Neuropathies and Disorders (52 papers) and Sphingolipid Metabolism and Signaling (29 papers). Jeffrey A. Cohen is often cited by papers focused on Multiple Sclerosis Research Studies (163 papers), Peripheral Neuropathies and Disorders (52 papers) and Sphingolipid Metabolism and Signaling (29 papers). Jeffrey A. Cohen collaborates with scholars based in United States, Canada and Switzerland. Jeffrey A. Cohen's co-authors include Stephen C. Reingold, Ludwig Kappos, Alan J. Thompson, Jerry S. Wolinsky, Chris H. Polman, Xavier Montalbán, Eva Havrdová, Fred Lublin, Massimo Filippi and Paul O’Connor and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Jeffrey A. Cohen

297 papers receiving 22.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

2011 7.6k citations Jeffrey A. Cohen, Eva Havrdová et al. Annals of Neurology profile →
Two types of astrocytes in cultures of developing rat white matter: differences in morphology, surface gangliosides, and growth characteristics

1983 657 citations Jeffrey A. Cohen et al. profile →
Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging.

1992 585 citations Francisco González‐Scarano, Jeffrey A. Cohen et al. profile →
Distal symmetric polyneuropathy: A definition for clinical research

2005 566 citations Jeffrey A. Cohen et al. Neurology profile →
Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls

2007 546 citations Myla Goldman, Jeffrey A. Cohen et al. Multiple Sclerosis Journal profile →
The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review

2015 371 citations Jeffrey A. Cohen, Per Soelberg Sørensen et al. Multiple Sclerosis Journal profile →
Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis

2017 302 citations Jeffrey A. Cohen et al. Multiple Sclerosis Journal profile →
A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview

2015 296 citations Jeffrey A. Cohen, Per Soelberg Sørensen et al. Multiple Sclerosis Journal profile →
Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions

2021 184 citations Jeffrey A. Cohen et al. profile →

Peers

Countries citing papers authored by Jeffrey A. Cohen

Since Specialization

Citations

This map shows the geographic impact of Jeffrey A. Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey A. Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey A. Cohen more than expected).

Fields of papers citing papers by Jeffrey A. Cohen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey A. Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey A. Cohen. The network helps show where Jeffrey A. Cohen may publish in the future.

Co-authorship network of co-authors of Jeffrey A. Cohen

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey A. Cohen. A scholar is included among the top collaborators of Jeffrey A. Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey A. Cohen. Jeffrey A. Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Volumetric MRI Comparing Longitudinal Change in MOGAD to NMOSD , MS and Healthy Controls, and Disability Associations 2025 ·Annals of Neurology ·Amy Kunchok, Moein Amin, (unknown), (unknown), Robert Bermel, (unknown), Justin Abbatemarco, Stephen E. Jones, Jeffrey A. Cohen, Daniel Ontaneda, Kunio Nakamura	0
2	Analyte heterogeneity analysis as a possible potency parameter for MSC 2024 ·Best Practice & Research Clinical Haematology ·David R. Kaplan, (unknown), (unknown), Hillard M. Lazarus, Jeffrey A. Cohen	0
3	Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups 2024 ·Neurology ·Mitzi Williams, Lilyana Amezcua, Stanley Cohan, Jeffrey A. Cohen, (unknown), Le H. Hua, Elisabeth B. Lucassen, Rebecca Piccolo, (unknown), James Stankiewicz	3
4	Longitudinal Disability, Cognitive Impairment, and Mood Symptoms in Patients With Anti-NMDA Receptor Encephalitis 2024 ·Neurology ·(unknown), Yadi Li, (unknown), Alex Milinovich, Justin Abbatemarco, Jeffrey A. Cohen, Daniel Ontaneda, Vineet Punia, Alex Rae-Grant, Rachel Galioto, Amy Kunchok	12
5	Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis 2024 ·Neurology Neuroimmunology & Neuroinflammation ·John Foley, Gilles Defer, Lana Zhovtis Ryerson, Jeffrey A. Cohen, Douglas L. Arnold, Helmut Butzkueven, Gary Cutter, Gavin Giovannoni, Joep Killestein, Heinz Wiendl, (unknown), (unknown), (unknown), Kyle Ferber, (unknown), (unknown), (unknown)	2
6	Review of the Longitudinal Management of Autoimmune Encephalitis, Potential Biomarkers, and Novel Therapeutics 2024 ·Neurology Clinical Practice ·(unknown), (unknown), Jeffrey A. Cohen, Rachel Galioto, Justin Abbatemarco, Amy Kunchok	5
7	The onset presentation of multiple sclerosis differs in Hispanic/Latinx Americans compared with non-Hispanic White Americans 2024 ·Multiple Sclerosis Journal ·Farren Briggs, Devon Conway, Carrie M. Hersh, Kathryn C. Fitzgerald, Ellen M. Mowry, Jeffrey A. Cohen, Daniel Ontaneda	2
8	Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology 2021 ·Neurology Clinical Practice ·Le H. Hua, Ahmed Z. Obeidat, Lilyana Amezcua, Jeffrey A. Cohen, Kathleen Costello, Jeffrey Dunn, Jeffrey M. Gelfand, Myla Goldman, Sarah Hopkins, Douglas Jeffery, Stephen Krieger, Scott D. Newsome, (unknown), Nancy L. Sicotte, Vijayshree Yadav, Erin E. Longbrake	2
9	A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment 2021 ·Multiple Sclerosis Journal ·Jeffrey A. Cohen, Michelle Cameron, Myla Goldman, Andrew Goodman, Aaron Miller, (unknown), Lily Llorens, Rajiv Patni, Robert Elfont, Reed Johnson	3
10	Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation 2019 ·Biology of Blood and Marrow Transplantation ·Jeffrey A. Cohen, Laura Baldassari, Harold Atkins, James D. Bowen, Christopher Bredeson, Paul A. Carpenter, John R. Corboy, Mark S. Freedman, Linda M. Griffith, Robert Lowsky, Navneet S. Majhail, Paolo A. Muraro, Richard A. Nash, Marcelo C. Pasquini, Stefanie Sarantopoulos, Bipin N. Savani, Jan Storek, Keith M. Sullivan, George E. Georges	72
11	Evaluating the efficacy and safety of 6-week extended interval dosing of natalizumab via a prospective, controlled, randomized, open-label, rater-blinded phase 3b study (P3.2-095) 2019 ·Neurology ·Nolan Campbell, Jeffrey A. Cohen, Heinz Wiendl, John Foley, Helmut Butzkueven, Lana Zhovtis Ryerson, Gavin Giovannoni, Douglas L. Arnold, Gilles Defer, Joep Killestein, Gary Cutter, Zheng Ren, Rachna Kasliwal, Giuseppina Stifano, Ih Chang, Pei‐Ran Ho	0
12	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study 2018 ·Multiple Sclerosis Journal ·Jeffrey A. Cohen, Giancarlo Comi, Douglas L. Arnold, Amit Bar‐Or, Krzysztof Selmaj, Lawrence Steinman, Eva Havrdová, Bruce Cree, Xavier Montalbán, Hans‐Peter Hartung, Vivian Huang, Paul Frohna, Brett E. Skolnick, Ludwig Kappos, (unknown)	39
13	Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial 2018 ·Multiple Sclerosis Journal ·Jeffrey A. Cohen, Samuel F. Hunter, Theodore R. Brown, Mark Gudesblatt, Ben Thrower, Lily Llorens, (unknown), (unknown), David Chernoff, Rajiv Patni	8
14	Efficacy Results of the Phase 2 Portion of the RADIANCE Trial: A Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 in Adults with Relapsing Multiple Sclerosis (P7.198) 2015 ·Neurology ·Gıancarlo Comı, Jeffrey A. Cohen, Douglas L. Arnold, Amit Bar‐Or, Sheila Gujrathi, Jeffrey Hartung, Allan Olson, Matthew Cravets, Paul Frohna, Krzysztof Selmaj	5
15	Immunogenicity of Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the CARE-MS II Study (P07.101) 2013 ·Neurology ·Per Soelberg Sørensen, Douglas L. Arnold, Jeffrey A. Cohen, Alasdair Coles, Christian Confavreux, Edward Fox, Hans Hartung, Eva Havrdová, Krzysztof Selmaj, Howard L. Weiner, Tamara Miller, Cary Twyman, Stephen Lake, David Margolin, Susan Richards, Crystal Sung, Michael Panzara, Alastair Compston	4
16	Patterns of cognitive impairment in relapsing-remitting and chronic progressive multiple sclerosis 1994 ·Murray Grossman, Carol L. Armstrong, Kris Onishi, Heidi Thompson, Barbara A. Schaefer, Keith Robinson, Mark D’Esposito, Jeffrey A. Cohen, (unknown), (unknown), Francisco González‐Scarano, Dennis L. Kolson, Cris S. Constantinescu, Donald H. Silberberg	26
17	Binding of type 3 reovirus by a domain of the sigma 1 protein important for hemagglutination leads to infection of murine erythroleukemia cells. 1992 ·Journal of Clinical Investigation ·D H Rubin, J. Denise Wetzel, William V. Williams, Jeffrey A. Cohen, (unknown), Terence S. Dermody	29
18	Peripheral neuropathy: causes and management in the elderly. 1990 ·PubMed ·Jeffrey A. Cohen, (unknown)	3
19	Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein. 1989 ·PubMed ·David B. Weiner, Y Kokai, Takuro Wada, Jeffrey A. Cohen, William V. Williams, Mark I. Greene	80
20	Structure and Regulation of Internal Image Idiotypes 1989 ·Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy ·William V. Williams, Robert Guy, Jeffrey A. Cohen, David B. Weiner, Mark I. Greene	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact